By clicking "Allow," you will be taken to a website that is independent of ViiV Healthcare. The site you linking to is not controlled or endorsed by ViiV Healthcare, and ViiV Healthcare is not responsible for the content provided on that site.
This site is exclusively for healthcare professionals in the US. It contains medical information about ViiV Healthcare medications.
It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Change in Healthcare Professional’s Identification, Counseling, and Adherence with Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women’s Health, Primary Care, and Infectious Diseases Sites: Findings from the EBONI Study
Patient Experiences at Month 6 after Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US
Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic
Improvement in Provider Experiences from Baseline to Month 12 with Integrating Cabotegravir Long-Acting (CAB LA) for PrEP into Care in an Implementation Science Trial (PILLAR)
Awareness and preferences for every 2 month long-acting injectable HIV Pre-Exposure Prophylaxis (PrEP) versus daily oral PrEP among cisgender women in the United States and the Dominican Republic
People with HIV in the US switching to cabotegravir + rilpivirine long-acting (CAB+RPV LA) from oral antiretroviral therapy (ART) have numerous real-world benefits, including high adherence and treatment satisfaction
Real-world Virologic and Safety Outcomes in People Living with HIV-1 Using Dolutegravir (DTG) + Lamivudine (3TC) in Asia Stratified by Viral Load (VL), Including in Individuals with High VLs
Real-world Experience with the Two-Drug Regimen Dolutegravir/Lamivudine for the Treatment of HIV-1 among Vulnerable People Living with HIV in Canada: Preliminary Results from a Chart Review Study
Evaluation of Weight Gain on Incident Hypertension among People Living with HIV-1 Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Randomized Clinical Trials through 96 Weeks
Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living with HIV-1 from Pregnancy Data with Combination DTG and/or 3TC Antiretroviral Therapies
PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a diverse sample of people with HIV-1 reporting high treatment satisfaction, good adherence, and high quality of life
Similar Efficacy, Safety and CD4 T-cell Increase up to Week 96 Observed with Fostemsavir (FTR)-Based Regimens in the BRIGHTE Study and Dolutegravir (DTG)-Based Regimens in the VIKING-3 Study in Individuals with Multidrug-Resistant (MDR) HIV-1
CD4 T-cell, CD4/CD8 Ratio Improvement and a General Reduction in Inflammatory Biomarkers with Low-Level Viremia (LLV) up to Week 192 with Fostemsavir (FTR)-Based Regimens in Individuals with Multidrug-Resistant (MDR) HIV-1
This site uses cookies and similar technologies (collectively, "cookies") to enhance your website experience and track the site's performance. These cookies are automatically enabled. By using this site, you agree to our use of these cookies in accordance with our Privacy Notice. Click on Privacy Choices below to manage your preferences, including to opt out of the sale or sharing of your information.
Managing Privacy Options
OPT OUT OF SALE AND SHARING OF INFORMATION
Your state law may allow you the right to opt out of the sale or sharing of your personal information for targeted advertising. You may opt out of such sale or share via the toggle available to you for "Targeting Cookies," and selecting the "Confirm my choices” button below. To limit sale or sharing of your information for targeting advertising offline, please see the "Cookies and Targeted Advertising Choices," section in the Privacy Notice and submit the required form.
Always Active
Necessary for the website to function appropriately, such as to store session data during a website visit, to manage cookie and tag preferences, and to protect the security of the website. In addition, some of these cookies are set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms.
Always Active
Enable the website to provide enhanced functionality and personalization, such as by helping us to measure how many visitors come to our websites, what sites our website visitors come from, and how often certain pages on our website are viewed. These cookies may be set by us or by third party providers, like our analytics service providers, whose services we have added to our pages.
Allow us to target and re-target you with relevant advertising. We and our advertising partners use information collected through these technologies to infer your interests in order to serve you more relevant advertisements on other sites. If you don’t allow these cookies, you will receive advertising, but it may be less relevant to you.
